List view / Grid view
18 November 2016 | By Niamh Louise Marriott, Digital Content Producer
The BRIDGE study involved 245 men with osteoporosis randomised 2:1 to receive either 210 mg romosozumab or placebo subcutaneously once monthly for 1 year...
22 July 2016 | By Niamh Louise Marriott, Digital Content Producer
UCB and Amgen today announced the submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for romosozumab, an investigational, monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture...
12 July 2016 | By Victoria White, Digital Content Producer
Certolizumab pegol is recommended as an option for people with severe rheumatoid arthritis when other drugs haven’t worked or aren’t suitable...
11 July 2016 | By Victoria White, Digital Content Producer
The SMC has accepted five new medicines for routine use in NHS Scotland including lung cancer treatments nivolumab and crizotinib...
10 June 2016 | By Victoria White, Digital Content Producer
In a Phase Ib study, bimekizumab showed fast and sustained efficacy on disease activity measures in both skin and joints and was well-tolerated...
21 March 2016 | By Victoria White
The study demonstrated a statistically significant increase in bone mineral density at the lumbar spine in men with osteoporosis treated with romosozumab...
29 February 2016 | By Victoria White
UCB’s Briviact (brivaracetam) has been authorised in the UK as an add-on treatment for partial onset seizures with or without secondary generalised seizures...
23 February 2016 | By Victoria White
The Phase III FRAME study evaluated UCB and Amgen's romosozumab in postmenopausal women with osteoporosis...
26 January 2016 | By Victoria White
NICE recommends the seven biological disease modifying drugs as options for treating severe rheumatoid arthritis which has not responded to intensive therapy with a combination of conventional DMARDs...
27 November 2015 | By Victoria White
Lannett has acquired KU from UCB for a total consideration of approximately US$1.23 billion...
3 September 2015 | By Victoria White
Lannett Company has entered into a definitive agreement to acquire UCB’s US generics subsidiary, Kremers Urban Pharmaceuticals, for $1.23 billion...
15 June 2015 | By Victoria White
UCB has announced data from a Phase 3 study that showed the substantial benefits, at 52 weeks, of adding Cimzia to optimised methotrexate treatment...
1 April 2015 | By Victoria White
UCB has announced it has entered an agreement with Dr. Reddy’s to sell its established brands in India, allowing it to focus on its neurology portfolio...
UCB has announced that its joint bid with five other UK-based organisations has been selected as a recipient of the Government’s 2014 Advanced Manufacturing Supply Chain Initiative (AMSCI), which will result in a £6.2 million grant to support the development of novel biologic treatments.
19 March 2015 | By Victoria White
UCB welcomes the Chancellor’s recognition in 2015 Budget of the relationship between scientific success and the future prosperity of the UK economy...
